H41A:XETRA:XETRA-HSBC World ESG Biodiversity Screened Equity UCITS ETF USD EUR (EUR)

ETF | Others |

Last Closing

USD 34.23

Change

0.00 (0.00)%

Market Cap

USD 4.87M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.56 (-1.12%)

USD 509.68B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.24 (-1.50%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.38 (-1.44%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.40 (-1.44%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.29 (-1.23%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.62 (-1.41%)

USD 101.50B
8R80:XETRA Amundi Index Solutions - Amund..

-1.12 (-0.79%)

USD 100.74B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.73 (-1.44%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+0.92 (+0.17%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.33 (-1.50%)

USD 79.79B

ETFs Containing H41A:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.06% 46% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.06% 45% F 47% F
Trailing 12 Months  
Capital Gain 12.40% 65% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.40% 65% D 65% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.60% 60% D- 58% F
Dividend Return 6.60% 58% F 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.28% 64% D 72% C
Risk Adjusted Return 71.09% 83% B 84% B
Market Capitalization 4.87M 5% F 4% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.